Biofy and Labormed complete the certification of Abby and begin operation from January 26

Biofy and Labormed announce the successful completion of the certification process for Abby, an innovative system for pathogen identification and antibiotic recommendation based on total DNA sequencing and artificial intelligence. Starting from January 26, the solution will officially enter operation, becoming part of Labormed's portfolio.

The conclusion of the certification phase represents an important milestone for both companies and practically validates the efficiency and robustness of the technology developed by Biofy. During the testing period, Abby demonstrated its ability to identify bacteria, detect antibiotic resistances, and recommend the most effective treatments in up to 4 hours — rather than days, as is the case with traditional methods.

With the operation active, the partnership expands market access to a technology that addresses one of the greatest challenges of modern healthcare: combating antimicrobial resistance. The integration of Abby into Labormed's laboratory routine reinforces the commitment of both companies to innovation, diagnostic agility, and support for clinical decision-making based on genomic data.

More than just the end of a technical phase, the start of operations symbolizes the consolidation of a strategic collaboration that unites biotechnology, artificial intelligence, and practical application, with a direct impact on the quality of diagnostics and the care of life.